Now, it’s worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 194% for ...

With immunology and inflammation blockbusters like AbbVie’s Skyrizi and Rinvoq reeling in nearly $7 billion combined in the ...

Nektar Therapeutics has pivoted from oncology to focus on autoimmune and inflammatory diseases. Read why I rate NKTR stock a ...

Delgocitinib has emerged as a promising treatment for CHE, addressing unmet needs and enhancing understanding of this complex condition, notes Raj Chovatiya, MD, PhD, MSCI.

For the primary endpoint, Eczema Area and Severity Index (EASI) improved by 53-61% in a dose-dependent manner across the ...

Topical corticosteroids are recommended as first-line treatment for all levels of atopic dermatitis, as well as for ...

Extended dosing of dupilumab in patients with AD has similar efficacy as standard dosing, with no significant affect seen on ocular adverse events.

Pipeline programs continue to advance, with four clinical data readouts anticipated in 2026; APG777 trial readout timelines accelerated, with Phase 1b in asthma and APEX 52-week Part A data in AD ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...

To enhance patient education and access to care, Pfizer has launched "AD Pedia Miniapp", China's first AI-powered specialized ...